Withdrawal of mycophenolate mofetil in stable renal transplant recipients

Bruce Kaplan, Herwig Ulf Meier-Kriesche, Mahesh Vaghela, Gary Friedman, Shamkant Mulgaonkar, Martin Jacobs

Research output: Contribution to journalArticlepeer-review

17 Scopus citations


Background. Mycophenolate mofetil (MMF) has been demonstrated to decrease episodes of acute rejection in renal transplant recipients during the first year after transplantation. The utility of MMF after 1 year is less clear. Methods. Forty-five stable renal transplant recipients on maintenance therapy of cyclosporine microemulsion, MMF, and prednisone had MMF withdrawn at approximately 1 year after transplantation. A matching concurrent group of 45 stable renal transplant recipients served as the case control group. Results. Two of 45 patients in the MMF withdrawal group suffered an acute rejection episode as opposed to 1 of 45 in the control group. Both patients who rejected in the withdrawal group had adequate cyclosporine levels and had no recent decrease in prednisone dose. There was no evidence of an increased incidence of proteinuria or increased creatinine levels in the MMF withdrawal group. Conclusion. In general, withdrawal of MMF in stable renal transplant recipients is well tolerated. No increased risk of rejection could be demonstrated in this patient group. A larger study will be needed to confirm our result.

Original languageEnglish (US)
Pages (from-to)1726-1728
Number of pages3
Issue number8
StatePublished - Apr 27 2000
Externally publishedYes

ASJC Scopus subject areas

  • Transplantation


Dive into the research topics of 'Withdrawal of mycophenolate mofetil in stable renal transplant recipients'. Together they form a unique fingerprint.

Cite this